MedWatch

Brazilian success: SynAct Pharma scores positive results with therapy for covid-19

After generating promising results in a phase II trial with the company's anti-inflammatory drug for treating covid-19, SynAct Pharma is looking into the possibility of launching phase III.

Photo: Pilar Olivares/Reuters/Ritzau Scanpix

SynAct Pharma has received encouraging results from the clinical trial which the company launched in April earlier this year.

In the trial, patients who had received SynAct Pharma's anti-inflammatory treatment going by the name of AP1189, showed significant effect compared with those given placebo treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs